Chinese vaccine proves 79.34 pct effective against COVID-19 in phase-3 study
BEIJING, Dec. 30 (Xinhua) -- A Chinese inactivated vaccine shows 79.34 percent efficacy against COVID-19, according to the interim results of the phase-3 clinical trials unveiled by its developer Wednesday.
The inactivated vaccine is developed by the Beijing Biological Products Institute Co., Ltd. under the China National Biotec Group (CNBG), which is affiliated to Sinopharm.
After a two-dose inoculation procedure, the vaccine receivers all produced high titers of antibodies, and the seroconversion rate of neutralizing antibodies reached 99.52 percent.
The results meet the requirements of technical standards of the World Health Organization and the standards stipulated by China's National Medical Products Administration (NMPA).
The company has submitted an application to the NMPA for conditioned market approval.
[ Editor: WPY ]
More From Guangming Online
Medics from Fujian leave for Shanghai to aid in battle against COVID-19 resurgence
New int'l land-sea transport service to Indo-China Peninsula launched
Another makeshift hospital under construction in Shanghai
Tourists view tulips in Suiping County, Henan
In pics: blooming gagea flowers on grassland in Zhaosu, Xinjiang
Greek workers stage 24-hour general strike over high prices